161 related articles for article (PubMed ID: 27222937)
1. Determination of amino acids in urine of patients with prostate cancer and benign prostate growth.
Sroka WD; Boughton BA; Reddy P; Roessner U; Słupski P; Jarzemski P; Dąbrowska A; Markuszewski MJ; Marszałł MP
Eur J Cancer Prev; 2017 Mar; 26(2):131-134. PubMed ID: 27222937
[TBL] [Abstract][Full Text] [Related]
2. Furan and p-xylene as candidate biomarkers for prostate cancer.
Jiménez-Pacheco A; Salinero-Bachiller M; Iribar MC; López-Luque A; Miján-Ortiz JL; Peinado JM
Urol Oncol; 2018 May; 36(5):243.e21-243.e27. PubMed ID: 29395956
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen in urine.
Breul J; Pickl U; Hartung R
Eur Urol; 1994; 26(1):18-21. PubMed ID: 7523129
[TBL] [Abstract][Full Text] [Related]
4. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
[TBL] [Abstract][Full Text] [Related]
5. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
[TBL] [Abstract][Full Text] [Related]
6. Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer.
Li C; Zang T; Wrobel K; Huang JT; Nabi G
Anal Bioanal Chem; 2015 May; 407(12):3393-404. PubMed ID: 25724369
[TBL] [Abstract][Full Text] [Related]
7. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.
Rehman I; Azzouzi AR; Catto JW; Allen S; Cross SS; Feeley K; Meuth M; Hamdy FC
Urology; 2004 Dec; 64(6):1238-43. PubMed ID: 15596215
[TBL] [Abstract][Full Text] [Related]
8. Detection of prostate cancer by an electronic nose: a proof of principle study.
Roine A; Veskimäe E; Tuokko A; Kumpulainen P; Koskimäki J; Keinänen TA; Häkkinen MR; Vepsäläinen J; Paavonen T; Lekkala J; Lehtimäki T; Tammela TL; Oksala NK
J Urol; 2014 Jul; 192(1):230-4. PubMed ID: 24582536
[TBL] [Abstract][Full Text] [Related]
9. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
10. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
Zhao H; Zhao X; Lei T; Zhang M
Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
[TBL] [Abstract][Full Text] [Related]
11. In the search of novel urine biomarkers for the early diagnosis of prostate cancer. Intracellular or secreted proteins as the target group? Where and how to search for possible biomarkers useful in the everyday clinical practice.
Katafigioti A; Katafigiotis I; Sfoungaristos S; Alamanis C; Stravodimos K; Anastasiou I; Roumelioti E; Duvdevani M; Constantinides C
Arch Ital Urol Androl; 2016 Oct; 88(3):195-200. PubMed ID: 27711093
[TBL] [Abstract][Full Text] [Related]
12. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer.
Ikeda I; Miura T; Kondo I
Br J Urol; 1996 Jan; 77(1):102-6. PubMed ID: 8653278
[TBL] [Abstract][Full Text] [Related]
13. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers.
Ma W; Diep K; Fritsche HA; Shore N; Albitar M
Genet Test Mol Biomarkers; 2014 Mar; 18(3):156-63. PubMed ID: 24512523
[TBL] [Abstract][Full Text] [Related]
15. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer.
Takeuchi S; Arai K; Saitoh H; Yoshida K; Miura M
J Urol; 1996 Nov; 156(5):1691-5. PubMed ID: 8863572
[TBL] [Abstract][Full Text] [Related]
16. Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.
Yan C; Kim YH; Kang HW; Seo SP; Jeong P; Lee IS; Kim D; Kim JM; Choi YH; Moon SK; Yun SJ; Kim WJ
J Korean Med Sci; 2015 Dec; 30(12):1784-92. PubMed ID: 26713053
[TBL] [Abstract][Full Text] [Related]
17. The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer.
Sardana G; Diamandis EP
Clin Biochem; 2009 Sep; 42(13-14):1483-6. PubMed ID: 19560453
[TBL] [Abstract][Full Text] [Related]
18. Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer.
Jedinak A; Curatolo A; Zurakowski D; Dillon S; Bhasin MK; Libermann TA; Roy R; Sachdev M; Loughlin KR; Moses MA
BMC Cancer; 2015 Apr; 15():259. PubMed ID: 25884438
[TBL] [Abstract][Full Text] [Related]
19. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
20. High level of phosphatidylcholines/lysophosphatidylcholine ratio in urine is associated with prostate cancer.
Li X; Nakayama K; Goto T; Kimura H; Akamatsu S; Hayashi Y; Fujita K; Kobayashi T; Shimizu K; Nonomura N; Ogawa O; Inoue T
Cancer Sci; 2021 Oct; 112(10):4292-4302. PubMed ID: 34328656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
